Istvan J. Enyedy
Principal Scientist
Biogen Idec, USA
USA
Biography
In the past 14 years Istvan J Enyedy has been involved in new target evaluation, hit finding, and hit-to-lead optimization projects for several types of target classes using both ligand and structure-based methods. He is coauthor on more than 30 publications and 9 patents/applications. He received his PhD in 1998 at Catholic University of America, Washington DC, and did postdoctoral training in Dr. Shaomeng Wang’s group at Georgetown University Medical Center, Washington DC. Between 2001 and 2008 he worked at Bayer Pharmaceuticals, West Haven CT and Novartis Institutes for Biomedical Research in Cambridge MA. Since August 2008 he has been working at Biogen Idec, in Cambridge MA.
Research Interest
Lead the Computational Chemistry Focus group with two direct reports. Supported drug discovery projects in oncology, immunology, and neurology. Proposed new target for oncology in collaboration with Pathology Group. Contributed to Oncology Project Initiation and Target Evaluation Groups. Initiated and supervised building and implementing in silico ADME prediction tools. Designed libraries for R-group optimization of cores considered by project teams. Supported hit-to-lead optimization for cardiovascular, diabetes, and oncology projects. Supported fragment-based screening efforts in Cambridge, MA. Proposed libraries for hit-to-lead optimization and corporate collection enrichment.